Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...

After 11 years of development and barely one full year of sales, New York–based Pfizer dumped the much-anticipated inhaled powder insulin product Exubera on 18 October. This was particularly bad ...

But in early April, the death blow was delivered: Pfizer, of New York, which in October had pulled its own inhaled insulin product, Exubera, from the market due to disappointing sales, said it is ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

Pfizer famously abandoned its Exubera inhaled insulin product 10 years ago over safety concerns, and because patients did not like the large and cumbersome delivery device. Despite these failures ...

Human inhaled insulin powder (HIIP ... clinical trial with Technosphere insulin and received lecturing fees from Pfizer Inc. and NovoNordisk. The author has no other relevant affiliations or ...

Analysts point to the commercial failure of the only other inhaled insulin to reach the market – Pfizer's Exubera. The drug was launched in 2006, but was not popular with doctors or patients.

The world's largest drug maker, Pfizer has announced that it intends to fast track its inhaled insulin Exubera in India. The world's largest drug maker, Pfizer has announced that it intends to ...